Vascular remodeling is a pathological condition with structural changes of blood vessels. Both inside-out and outside-in hypothesis have been put forward to describe mechanisms of vascular remodeling. An integrated model of these two hypotheses emphasizes the importance of immune cells such as monocytes/macrophages, T cells, and dendritic cells. These immune cells are at the center stage to orchestrate cellular proliferation, migration, and interactions of themselves and other vascular cells including endothelial cells (ECs), vascular smooth muscle cells (VSMCs), and fibroblasts. These changes on vascular wall lead to inflammation and oxidative stress that are largely responsible for vascular remodeling. Mineralocorticoid receptor (MR) is a classic nuclear receptor. MR agonist promotes inflammation and oxidative stress and therefore exacerbates vascular remodeling. Conversely, MR antagonists have the opposite effects. MR has direct roles on vascular cells through non-genomic or genomic actions to modulate inflammation and oxidative stress. Recent studies using genetic mouse models have revealed that MR in myeloid cells, VSMCs and ECs all contribute to vascular remodeling. In conclusion, data in the past years have demonstrated that MR is a critical control point in modulating vascular remodeling. Studies will continue to provide evidence with more detailed mechanisms to support this notion. What is vascular remodeling? A simple and straightforward and possibly the most correct answer is that any structural changes of blood vessels are called vascular remodeling [1]. The causes of these changes range from pressure, flow and atherosclerotic stimuli, to mechanical injury such as balloon angioplasty and stent implantation during endovascular interventions. The changes can be on the vascular wall, the luminal diameter, or both. Although the changes on the vascular wall and luminal diameter often happen together, there are situations that only one of them alters. For example, Glagov and colleagues [2] found that the luminal diameter of atherosclerotic human coronaries remained constant until the percent stenosis exceeded 40%, whereas the vascular wall had dramatically changed because of atherosclerosis. These structural changes are often accompanied by functional alterations of the blood vessels. Therefore, vascular remodeling is closely associated with the pathophysiology of a series of cardiovascular diseases such as atherosclerosis and restenosis, cerebrovascular diseases such as stroke, as well as hypertension. In this review, I will discuss the roles of mineralocorticoid receptor, a member of the nuclear receptor superfamily that controls numerous critical aspects of cellular functions under physiological or pathophysiological conditions, in vascular remodeling. This article will not cover vascular remodeling in embryonic development or tumor growth, even though structural changes of blood vessels also happen in both processes [3, 4] .
What is vascular remodeling? A simple and straightforward and possibly the most correct answer is that any structural changes of blood vessels are called vascular remodeling [1] . The causes of these changes range from pressure, flow and atherosclerotic stimuli, to mechanical injury such as balloon angioplasty and stent implantation during endovascular interventions. The changes can be on the vascular wall, the luminal diameter, or both. Although the changes on the vascular wall and luminal diameter often happen together, there are situations that only one of them alters. For example, Glagov and colleagues [2] found that the luminal diameter of atherosclerotic human coronaries remained constant until the percent stenosis exceeded 40%, whereas the vascular wall had dramatically changed because of atherosclerosis. These structural changes are often accompanied by functional alterations of the blood vessels. Therefore, vascular remodeling is closely associated with the pathophysiology of a series of cardiovascular diseases such as atherosclerosis and restenosis, cerebrovascular diseases such as stroke, as well as hypertension. In this review, I will discuss the roles of mineralocorticoid receptor, a member of the nuclear receptor superfamily that controls numerous critical aspects of cellular functions under physiological or pathophysiological conditions, in vascular remodeling. This article will not cover vascular remodeling in embryonic development or tumor growth, even though structural changes of blood vessels also happen in both processes [3, 4] .
The mechanisms of vascular remodeling: the inside-out and outside-in hypotheses
At least two different models have been put forward to describe the process of vascular remodeling, the inside-out hypothesis and outside-in hypothesis [5, 6] . Traditionally, the vascular remodeling is considered as an inside-out process. In this model, loss of endothelial integrity is a starting point followed by expression of surface adhesion molecules and inflammatory mediators that propel adhesion and transmigration of circulating monocytes into vascular wall. The causes of endothelial injury include mechanical injury, chemical stimuli, insulin resistance and associated glucose intolerance, dyslipidemia, hypertension, increased oxidation, thrombosis, and vascular inflammation [7] . Monocytes further differentiate into macrophages in the vascular wall and traditionally this process had been considered as a continuous one for the presence of monocytes/macrophages to function without excessive proliferation in the progression of vascular remodeling [8] . However, recent studies have demonstrated that in the process of atherosclerosis macrophages in the plaque maintain its population largely by proliferation after the initial migration of monocytes [9] . Either way, macrophages in the vascular wall interact with vascular smooth muscle cells (VSMCs) in the media directly or through secreted inflammatory chemokines, cytokines and reactive oxygen species (ROS). Consequently, VSMCs proliferate and migrate to subendothelial space and participate in repairing of damaged endothelium, formation of plaque or neointima, and vascular remodeling. In addition, VSMCs may dedifferentiate into myofibroblasts, contributing to vascular remodeling [5] . Other immune cells such as neutrophils, dendritic cells (DCs), T cells, B cells, and mast cells also play important roles in development and progression of atherosclerosis [10] . Fibroblasts are in general considered as bystanders in this model.
In contrast, the outside-in hypothesis proposes that injury and immune response are initiated in the adventitia and progressed inward to the media and intima [5, 6] . In this model, fibroblasts in the adventitia are highly active. In response to vascular stress or injury, adventitia fibroblasts are often among the first cells to be activated in the vascular wall, accompanied by activation of immune cells such as T cells, DCs, and macrophages. Besides their traditional function of secreting extracellular matrix (ECM), activated and highly proliferated fibroblasts play central roles in vascular remodeling through the following aspects. First, these activated fibroblasts are considered as capable of executing immune functions. They express receptors such as toll-like receptors (TLRs) and NOD-like receptors (NLRs) to mediate immune response. Further, they produce chemokines and cytokines such as monocyte chemotactic protein-1 (MCP1), regulated upon activation, normal T cell expressed and secreted (RANTES), interleukin 6 (IL6), and stromal cell-derived factor 1 (SDF-1). Secondly, fibroblasts interact with activated immune cells (T cells, DCs, and macrophages), ECs and VSMCs, either directly through cell-cell interactions or through chemokines, cytokines and ROS. Macrophages in this model are mostly regarded as resident ones or being differentiated from monocytes recruited from the vasa vasorum of the adventitia locally. In addition, proliferated fibroblasts can migrate to the media and intima, or differentiate into myofibroblasts that subsequently migrate to the media and intima, contributing to vascular remodeling [11] .
An integrated model of mechanisms: immune cells at the center stage of vascular remodeling
The two seemly contrasting hypotheses can come together and therefore I propose an integrated model for the mechanisms of vascular remodeling (Figure 1 ). For instance, in the procedure of stent, dramatic endothelial damages are accompanied by stretch stimulus of the whole blood vessels including the adventitia. It is possible that both mechanisms execute and propel each other. The inside-out process leads to macrophage accumulation in the subendothelial space and interacting with endothelial cells (ECs) and VSMCs. The macrophages may also accumulate in the adventitia and interact with fibroblasts and other immune cells, which in turn induce an outside-in process. The adventitia may also sense the stretch at the same time of endothelial injury and ignite an outside-in process by activating local macrophages, fibroblasts, T cells, and DCs. Of course, it is possible that the inside-out process is more dominant in pathological conditions such as atherosclerosis and the outside-in process is more dominant in others such as hypertension.
In either inside-out, outside-in, or integrated hypothesis, the immune cells play central roles in vascular remodeling. They respond to stress and injury, migrate into or proliferate in the vascular wall, and interact with other vascular cells. Monocytes/macrophages are a subset of these immune cells that have drawn much attention. Interestingly, macrophages predominantly accumulate in the adventitia in various models of vascular remodeling such as angiotensin II (Ang II)-induced, pressure overload-induced, and wire injuryinduced [12] [13] [14] , although macrophages-derived foam cells largely accumulate in the subendothelial area to form plaque in atherosclerosis. This implies that even if the macrophages come from the systemic circulation according to the inside-out hypothesis, these cells can ultimately dwell in the adventitia and interact with cells including fibroblasts and other immune cells there. These immune cells (monocytes/macrophages, T cells, DCs) interact with each other and with ECs, VSMCs, and fibroblasts, driving the whole process of vascular remodeling (Figure 1 ). Endothelial injuries initiate an inside-out process that leads to macrophage accumulation in the subendothelial space and interacting with endothelial cells and vascular smooth muscle cells through cell-cell interactions or secreted chemokines, cytokines and reactive oxygen species (ROS). Macrophages also migrate to and accumulate in the adventitia and interact with fibroblasts and other immune cells, which in turn induce an outside-in process. Simultaneously, the adventitia senses the stress and ignites an outside-in process by activating local macrophages, fibroblasts, T cells, and dendritic cells, all of which ultimately propel the inside-out process. In such way, the inside-out process and outside-in process act in concert and reinforce each other, being orchestrated by immune cells at the center stage and driving the whole course of vascular remodeling.
Mineralocorticoid receptor and vascular remodeling
Mineralocorticoid receptor (MR) is a classic steroid receptor in the nuclear receptor superfamily [15] . To exert its genomic actions, MR binds to mineralocorticoids (primarily aldosterone), translocates into nucleus, binds as homodimers to response elements of target genes, and therefore regulates their expression. The target genes of MR include those important in water-electrolyte homeostasis and blood pressure regulation, inflammation, oxidative stress, and fibrosis [16] . Recent studies have revealed that MR also has non-genomic actions by interactions with signaling pathways such as epidermal growth factor (EGF)/EGFR pathway and Ang II/type 1 Ang II receptors (AT1R) pathway [16] .
It is now well accepted that the function of MR is far beyond its traditional roles in epithelial cells to control water-electrolyte homeostasis and blood pressure. Clinical studies have continuously and convincingly demonstrated the effectiveness of MR antagonists (spironolactone and eplerenone) in treating heart failure patients [1719].
Mounting evidence from basic research has illustrated the critical functions of this nuclear receptor in cardiovascular system.
MR is expressed in vascular cells and the vasculature is generally regarded as an aldosterone-responsive tissue [20] . The concentration of glucocorticoids in the bloodstream is over 100 times higher than that of aldosterone and MR binds to both with similar affinity. Therefore, MR has the potential to bind to aldosterone only in tissues that express 11β-hydroxysteroid dehydrogenase type 2 (11βHSD2), an enzyme that inactivates glucocorticoids. Traditionally, kidney and colon are considered as aldosterone sensitive tissues because of the high level of expression of 11βHSD2. More recent studies, however, have revealed that vascular cells including VSMCs and ECs express 11βHSD2 as well, indicating that blood vessels are aldosterone-responsive. It remains to be determined whether this enzyme is expressed in macrophages or other immune cells.
Aldosterone and vascular remodeling
Both epidemiological studies and animal studies have shown the importance of aldosterone in vascular remodeling.
Circulating level of aldosterone is an independent predictor of cardiovascular ischemia according to epidemiological studies [2123] . When blood pressure is comparable, patients with hyperaldosteronism have drastically increased risk of stroke and myocardial infarction. These results suggest that aldosterone may promote atherosclerosis and plaque rupture in humans independent of its impact on blood pressure and that aldosterone and MR play important roles in vascular biology. Animal studies have also shown that aldosterone increases atherosclerosis in apoE knockout mice and this effect can be attenuated by blood pressure reduction [24] . More recently, aldosterone was found to promote early atherosclerosis and plaque inflammation in apoE knockout mice at a lower dose that did not elevate blood pressure, indicating that aldosterone may also directly affect atherosclerosis in animal models independent of its impact on blood pressure [25] . In addition, aldosterone infusion induces vascular fibrosis and remodeling in rats in the setting of high salt [26] . In a swine model of balloon angioplasty aldosterone tends to exacerbate collagen accumulation and constrictive remodeling of coronary arteries [27] .
Aldosterone increases inflammation and oxidative stress in different vascular cells [26, 28, 29] . MR activation stimulates infiltration of inflammatory cells including monocytes, macrophages and lymphocytes and promotes expression of inflammatory markers in the vasculature. Meanwhile, MR activation upregulates oxidative stress by increasing expression and activity of NADPH oxidases (NOX), production of ROS, and mitochondrial electron transport uncoupling. Given the vicious cycle of inflammation and oxidative stress, excessive aldosterone stimulates the two components that propel each other, promoting proliferation and migration of vascular cells, ECM deposition, and ultimately vascular remodeling.
MR antagonists and vascular remodeling
Both eplerenone and spironolactone attenuate collagen accumulation and constrictive remodeling of coronary arteries without affecting the size of neointima in a swine model of balloon angioplasty [27] . In a swine model of stenting, eplerenone suppresses neointima formation, vascular fibrosis and remodeling [30] . Spironolactone inhibits Ang IIinduced increase in media-to-lumen ratio of mesenteric resistance arteries and decrease in acetylcholine-induced vasodilation while decreasing blood pressure and oxidative stress in a rat model [31] . Similarly, structural and functional abnormalities induced by high salt in spontaneously hypertensive rats were inhibited by eplerenone [32] . Subsequent data using Ang II overproducing transgenic mice showed that spironolactone improved vascular remodeling independent of blood pressure [33] . More recently, spironolactone has been shown to attenuate pulmonary vascular resistance and pulmonary vascular remodeling in an experimental pulmonary hypertension mouse model [34] . In addition, MR antagonists can inhibit atherosclerosis in different animal models [3537] . Mechanistically, blockade of MR by antagonists inhibits oxidative stress and/or inflammation and therefore breaks the vicious cycle. These data further demonstrated the importance of MR in vascular remodeling, providing foundations for further investigations on cell type-specific functions of MR.
Myeloid MR and vascular remodeling
Myeloid cells play important roles in atherosclerosis and restenosis. Functions of myeloid MR in vascular remodeling have been studied using a knockout mouse model. When challenged with a combination of a NOS inhibitor, N G -nitro-L-arginine methyl ester (L-NAME), and Ang-II, myeloid MR knockout (MMRKO) mice had decreased vascular fibrosis and remodeling, in addition to suppressed cardiac remodeling [12] . Macrophage infiltration in heart and aorta was almost completely blocked by myeloid MR deletion. Intriguingly, blood pressure was higher in the MMRKO mice, suggesting that the cardiovascular protection of myeloid MR deficiency was not because of its impact on blood pressure. Further, MR activation by aldosterone stimulated pro-inflammatory M1 polarization of macrophages and that MRKO or MR antagonists resulted in anti-inflammatory M2 polarization of macrophages by regulating a host of M1 and M2 genes. These M1 genes include interleukin 1 (IL1), IL6, IL12, monocyte chemotactic protein-1 (MCP1), regulated upon activation, normal T cell expressed and secreted (RANTES), and tumor necrosis factor- (TNF). M2 genes include arginase 1 (Arg1), chemokine (C-C motif) ligand 7 (CCL7), CCL17, found in inflammatory zone 1 (FIZZ1), coagulation factor XIII a1 (F13a1), IL10, macrophage scavenger receptor (MSR), and T-lymphocytederived eosinophil chemotactic factor (YM1). Additionally, MRKO or MR antagonists decreased expression of profibrotic genes including plasminogen activator inhibitor-1 (PAI1), transforming growth factor  (TGF), as well as increased expression of anti-fibrotic genes including cysteine-rich, angiogenic inducer 61 (CYR61), high-temperature requirement A1 (HTRA1), and pyruvate dehydrogenase kinase 4 (PDK4). More recently, these phenotypes were also demonstrated in human monocytes/macrophages [38, 39] . Therefore, MR acts as a strong control point for macrophage polarization that may ultimately explain the beneficial effects of MRKO on vascular remodeling ( Figure  2 ). The detailed mechanisms are still under intensive investigations. MRKO or antagonist also decreases pro-fibrotic gene expression while increases anti-fibrotic gene expression. These effects ultimately translate into deleterious impacts of aldosterone and beneficial impacts of MRKO or antagonist on vascular remodeling. IL1: interleukin 1; MCP1: monocyte chemotactic protein-1; RANTES: regulated upon activation, normal T cell expressed and secreted; TNF: tumor necrosis factor-; Arg1: arginase 1; CCL7: chemokine (C-C motif) ligand 7; FIZZ1: found in inflammatory zone 1; F13a1: coagulation factor XIII a1; MSR: macrophage scavenger receptor; YM1: T-lymphocyte-derived eosinophil chemotactic factor; PAI1: plasminogen activator inhibitor-1; TGF: transforming growth factor ; CYR61: cysteine-rich, angiogenic inducer, 61; HTRA1: high-temperature requirement A1; PDK4: pyruvate dehydrogenase kinase 4.
VSMC MR and vascular remodeling

VSMC-specific knockout of MR (SMRKO) effectively
blocked age-associated hypertension through decreasing vascular myogenic tone and vasoconstriction response, without alterations in vascular structure or renal function [40] . However, in a wire-induced carotid injury model in combination with aldosterone infusion, SMRKO dramatically decreased VSMC proliferation and vascular fibrosis that were induced by aldosterone or injury alone, through a placental growth factor/type 1 vascular endothelial growth factor receptor (VEGFR1) pathway [41] .
At the cellular level, MR plays direct roles in VSMCs through rapid non-genomic pathways or slower genomic effects ( Figure 3) . A large amount of data have been generated on studying the non-genomic actions of MR in VSMCs [20, 26, 42, 43] . Aldosterone has been shown to rapidly transactivate EGFR or platelet-derived growth factor receptor (PDGFR), which are followed by activation of nonreceptor tyrosine kinase c-Src. Subsequently, c-Src phosphorylates and activates mitogen-activated protein kinases (MAPK) including ERK, JNK, and P38. Meanwhile, c-Src upregulates redox pathways through activation of NOX. Genomic actions of MR have also been reported in VSMCs.
MR has been demonstrated to regulate expression of genes such as dual specificity protein phosphatase 1 (Dusp1), plasminogen activator inhibitor-1 (PAI-1), connective tissue growth factor (CTGF), collagen I, and collagen III [20] . Importantly, these phenotypes of aldosterone can be inhibited by MR antagonists, indicating the dependency of MR. Furthermore, both non-genomic and genomic actions are potentiated by crosstalk between Ang II/AT1R pathway and aldosterone/MR pathway [20, 42] . In the end, these non-genomic and genomic actions of MR in VSMCs lead to inflammation, oxidative stress, proliferation, migration, and ECM deposition, contributing to vascular remodeling.
EC MR and vascular remodeling
Either at baseline or stimulated with Ang II or endothelin 1, endothelial cell-specific MR overexpression (ECMROE) mice had significantly elevated blood pressure that could be reversed by MR antagonist. Furthermore, the resistance arteries from ECMROE mice had increased contractile response to vasoconstrictors. Intriguingly, despite these func- tional changes, no morphological alterations were observed between ECMROE mice and littermate control mice [44] . EC MR knockout (ECMRKO) prevented endothelial dysfunction, measured by endothelium-dependent vasodilation of aortic rings, in mouse models of both obesity and aldosterone infusion [45] . Further experiments showed that ECMRKO could prevent aldosterone-induced endothelial dysfunction in aortas but not in mesenteric arteries, suggesting differential function of endothelial MR in large conduit arteries vs. resistance vessels [46] . Blood pressure was not different between ECMRKO mice at baseline or stimulated with DOCA. The functions of endothelial MR in vascular remodeling are worth further exploration in different models and with more mechanistic depth.
At the cellular level, MR also plays direct roles in ECs (Figure 4) . In vascular ECs, aldosterone has been shown to promote expression of intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) and therefore adhesion of leukocytes [47, 48] . Aldosterone induces ROS generation in ECs by activation of NOX through a c-Src/Rac1 pathway or by suppression of glucose-6-phosphate dehydrogenase (G6PD) activity, in an MR-dependent manner [49, 50] . Further, although there are conflicting data [51] , MR activation has been shown to decrease endothelial nitric oxide synthase (eNOS) and production of nitric oxide (NO) by activation of protein phosphatase 2A (PP2A) [20, 52] . In addition, aldosterone has been shown to activate ERK through phosphoinositide 3-kinase (PI3K) in ECs [51] . A link between aldosterone and EGFR has also been proposed in ECs [43] . It is likely that in these cells aldosterone also transactivates EGFR that subsequently activates c-Src, a pathway that is operated in VSMCs. It remains to be determined whether PP2A and PI3K are activated by c-Src, which has been reported in other systems, or by other mechanisms. Consequently, MR activation in ECs promotes inflammation, oxidative stress, and endothelial dysfunction, contributing to vascular remodeling.
Conclusion and future directions
Vascular remodeling is a complicated pathological process involving multiple types of cells. Inflammation and oxidative stress are the major driving forces of vascular remodeling. Studies in the past years have demonstrated that MR is a critical control point to break the vicious cycle of inflammation and oxidative stress in various vascular cells. These data support that MR is a potential target for modulating vascular remolding and warrant clinical studies to test therapeutic effects of MR antagonists that have already been used for heart failure patients.
MR will continue to be an interesting and important research topic in vascular remodeling with many questions unanswered. For instance, functions of MR in T cells and DCs in vascular remodeling are still to be investigated. MR is abundantly expressed in DCs and may be also expressed in T cells at a much lower level [53, 54] . It has been shown that aldosterone promotes activation of CD8 + T cells and Th17 polarization of CD4 + T cells and that these effects are dependent on activation of MR and modulation of DC function by aldosterone [54] . More recently, it has been reported that MR activation reduces the amount of circulating naïve CD4 + and CD8 + T cells in human subjects, further suggesting important functions of MR in T cells [55] . However, direct roles of MR in T cells or DCs have not been reported in any setting of vascular remodeling. In addition, detailed molecular mechanisms of MR in immune cells and vascular cells need to be further delineated.
